Dominik Horn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dominik Horn has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Jürgen Hoffmann
Department of Oral and Cranio-Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, Germany
6 shared publicationsKolja Freier
Department of Oral and Cranio-Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, Germany
6 shared publications- Christian Freudlsperger
Department of Oral and Maxillofacial Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany
5 shared publications Jochen Hess
Department of Otorhinolaryngology, Head and Neck Surgery Heidelberg University Hospital Heidelberg Germany
3 shared publications- Julius Moratin
University of Heidelberg, Department of Oral and Cranio-Maxillofacial Surgery, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany
3 shared publications Esther Herpel
Institute of Pathology, University Hospital Heidelberg Heidelberg Germany
2 shared publications
Latest Publications
- Open Access
- 28 September 2021
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 26 (2) , 2055-2064
Clinical outcome and prognostic factors in recurrent oral squamous cell carcinoma after primary surgical treatment: a retrospective study
Objectives: Survival for patients with recurrent oral squamous cell carcinoma is usually poor, and the most effective treatment has not yet been clearly defined. The present study evaluates the outcome in radiotherapy-naïve patients after recurrence of oral squamous cell carcinoma with respect to different treatment modalities including surgery, radiation, chemoradiation, and palliative treatment.Patients and methods: In this retrospective study, we included all patients with primary oral squamous cell carcinoma who received exclusively surgical therapy between 2010 and 2020 and who suffered from locoregional recurrence in their follow-up. Patients with previous adjuvant therapy were excluded from this protocol. Clinical and pathological parameters were collected and statistically evaluated. Survival analysis was performed according to Kaplan–Meier. The primary endpoints were overall and progression-free survival in dependance of treatment strategy for recurrent tumors.Results: Out of a total of 538 patients with surgically treated primary oral squamous cell carcinoma, 76 patients met the inclusion criteria. The mean follow-up was 38 ± 32 months. Patients who received surgically based therapy had a significantly better outcome in terms of disease-free survival (DFS) and overall survival (OS) (DFSp < 0.001; OSp < 0.001). The presence of regional metastases and a short disease-free interval (DFI) between primary and recurrent cancer were significant predictors for adverse outcomes (DFIp < 0.001).Conclusion: We recommend primary surgical therapy for radiotherapy-naïve patients with recurrent oral squamous cell carcinoma, supplemented by risk-adapted adjuvant therapy.Clinical relevance: Surgical therapy continues to play a central role in the treatment of radiotherapy-naïve patients with recurrent oral squamous cell carcinoma.
- 28 September 2021
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 26 (2) , 2055-2064
Open AccessClinical outcome and prognostic factors in recurrent oral squamous cell carcinoma after primary surgical treatment: a retrospective study
Objectives: Survival for patients with recurrent oral squamous cell carcinoma is usually poor, and the most effective treatment has not yet been clearly defined. The present study evaluates the outcome in radiotherapy-naïve patients after recurrence of oral squamous cell carcinoma with respect to different treatment modalities including surgery, radiation, chemoradiation, and palliative treatment.Patients and methods: In this retrospective study, we included all patients with primary oral squamous cell carcinoma who received exclusively surgical therapy between 2010 and 2020 and who suffered from locoregional recurrence in their follow-up. Patients with previous adjuvant therapy were excluded from this protocol. Clinical and pathological parameters were collected and statistically evaluated. Survival analysis was performed according to Kaplan–Meier. The primary endpoints were overall and progression-free survival in dependance of treatment strategy for recurrent tumors.Results: Out of a total of 538 patients with surgically treated primary oral squamous cell carcinoma, 76 patients met the inclusion criteria. The mean follow-up was 38 ± 32 months. Patients who received surgically based therapy had a significantly better outcome in terms of disease-free survival (DFS) and overall survival (OS) (DFSp < 0.001; OSp < 0.001). The presence of regional metastases and a short disease-free interval (DFI) between primary and recurrent cancer were significant predictors for adverse outcomes (DFIp < 0.001).Conclusion: We recommend primary surgical therapy for radiotherapy-naïve patients with recurrent oral squamous cell carcinoma, supplemented by risk-adapted adjuvant therapy.Clinical relevance: Surgical therapy continues to play a central role in the treatment of radiotherapy-naïve patients with recurrent oral squamous cell carcinoma.
- 2 July 2019
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 195 (9) , 819-829
Definitive radiotherapy vs. postoperative radiotherapy for lower gingival carcinomas of the mandible
To assess radiotherapy (RT) outcomes in patients with gingival carcinoma and growth up to or involvement of the lower jaw bone.
- 2 July 2019
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 195 (9) , 819-829
Definitive radiotherapy vs. postoperative radiotherapy for lower gingival carcinomas of the mandible
To assess radiotherapy (RT) outcomes in patients with gingival carcinoma and growth up to or involvement of the lower jaw bone.
- Open Access
Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma
Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) forms a distinct tumor entity with better survival clinical outcome. Numerous underlying molecular mechanisms have been postulated for differences in treatment response, but the impact of MEK/ERK signaling, a main driver of carcinogenesis in various cancers including OPSCC and key player mediating therapy resistance remains elusive. In a retrospective experimental cohort study, primary tumor samples from OPSCC patients (n = 124) were available on tissue microarrays (TMAs) and expression levels of phosphorylated ERK1/2 (pERK1/2) were detected by immunohistochemical staining. Correlations of pERK1/2 expression patterns with clinicopathological features and clinical outcome were evaluated by statistical analysis. A low pERK1/2 expression was strongly associated with HPV-related OPSCC, while primary tumors with high pERK1/2 staining showed a distinctly worse survival outcome and were associated with higher cellular differentiation. Co-activation of both ERK1/2 and AKT was a common event and was associated with unfavorable prognosis in our cohort. However, the combinatorial analysis of pAKT (Ser473) and pERK1/2 did not strengthen the predictive power of pERK1/2, suggesting that pERK1/2 plays a more significant function in OPSCC. In summary, our data provide a compelling experimental and statistical evidence that low levels of tumor cell intrinsic ERK1/2 activation contribute at least in part to the favorable outcome of HPV-related OPSCC. On the other hand, presented findings indicate that non-HPV-related OPSCC with elevated ERK phosphorylation are at high risk for treatment failure and might benefit from targeted therapy of MEK/ERK signaling.
Open AccessDifferential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma
Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) forms a distinct tumor entity with better survival clinical outcome. Numerous underlying molecular mechanisms have been postulated for differences in treatment response, but the impact of MEK/ERK signaling, a main driver of carcinogenesis in various cancers including OPSCC and key player mediating therapy resistance remains elusive. In a retrospective experimental cohort study, primary tumor samples from OPSCC patients (n = 124) were available on tissue microarrays (TMAs) and expression levels of phosphorylated ERK1/2 (pERK1/2) were detected by immunohistochemical staining. Correlations of pERK1/2 expression patterns with clinicopathological features and clinical outcome were evaluated by statistical analysis. A low pERK1/2 expression was strongly associated with HPV-related OPSCC, while primary tumors with high pERK1/2 staining showed a distinctly worse survival outcome and were associated with higher cellular differentiation. Co-activation of both ERK1/2 and AKT was a common event and was associated with unfavorable prognosis in our cohort. However, the combinatorial analysis of pAKT (Ser473) and pERK1/2 did not strengthen the predictive power of pERK1/2, suggesting that pERK1/2 plays a more significant function in OPSCC. In summary, our data provide a compelling experimental and statistical evidence that low levels of tumor cell intrinsic ERK1/2 activation contribute at least in part to the favorable outcome of HPV-related OPSCC. On the other hand, presented findings indicate that non-HPV-related OPSCC with elevated ERK phosphorylation are at high risk for treatment failure and might benefit from targeted therapy of MEK/ERK signaling.
- 1 March 2019
- Published by Wiley in Head & Neck
- Vol. 41 (8) , 2484-2491
Upregulation of PD‐L1 and PD‐L2 in neck node metastases of head and neck squamous cell carcinoma
Background: This study aimed on evaluating the expression levels of the immune checkpoint proteins, PD‐L1 and PD‐L2, in tissue specimens of 175 oral squamous cell carcinomas (OSCC) and 33 corresponding lymph node metastases (LNM).Methods: Tissue microarrays of primary OSCC and matched LNM were investigated via immunohistochemistry regarding PD‐L1/PD‐L2 expression. Results were compared for primary tumors and corresponding metastases and correlated with clinicopathological data.Results: PD‐L1 expression in cancer cells correlated significantly with tumor size, and the presence of regional metastases (P < 0.01). PD‐L1 expression was significantly higher in metastases as compared to primary OSCC (P < 0.05). Overall survival was significantly worse in patients with higher levels of PD‐L1 and PD‐L2 score (P < 0.05).Conclusions: This is the first publication to compare PD‐L1 and PD‐L2 expression in primary OSCC and matched LNM. The results indicate that anti‐PD‐1 therapy may be of therapeutic use even in early stage OSCC to prevent further progression.
- 1 March 2019
- Published by Wiley in Head & Neck
- Vol. 41 (8) , 2484-2491
Upregulation of PD‐L1 and PD‐L2 in neck node metastases of head and neck squamous cell carcinoma
Background: This study aimed on evaluating the expression levels of the immune checkpoint proteins, PD‐L1 and PD‐L2, in tissue specimens of 175 oral squamous cell carcinomas (OSCC) and 33 corresponding lymph node metastases (LNM).Methods: Tissue microarrays of primary OSCC and matched LNM were investigated via immunohistochemistry regarding PD‐L1/PD‐L2 expression. Results were compared for primary tumors and corresponding metastases and correlated with clinicopathological data.Results: PD‐L1 expression in cancer cells correlated significantly with tumor size, and the presence of regional metastases (P < 0.01). PD‐L1 expression was significantly higher in metastases as compared to primary OSCC (P < 0.05). Overall survival was significantly worse in patients with higher levels of PD‐L1 and PD‐L2 score (P < 0.05).Conclusions: This is the first publication to compare PD‐L1 and PD‐L2 expression in primary OSCC and matched LNM. The results indicate that anti‐PD‐1 therapy may be of therapeutic use even in early stage OSCC to prevent further progression.
- 1 March 2019
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 47 (3) , 523-529
MicroRNA expression correlates with disease recurrence and overall survival in oral squamous cell carcinoma
- 1 March 2019
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 47 (3) , 523-529
MicroRNA expression correlates with disease recurrence and overall survival in oral squamous cell carcinoma
- 20 November 2018
- Published by Wiley in Head & Neck
- Vol. 40 (12) , 2685-2694
Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma
Background: Cortactin (CTTN) is located on chromosome 11q13 and is associated with invasiveness in various cancer entities. CTTN protein expression could be a prognosticator of oral squamous cell carcinoma (OSCC) in terms of recurrence and survival.Methods: CTTN‐dependent invasion was performed using migration assay in human papillomavirus‐negative head and neck squamous cell carcinoma (HNSCC) cells. Cortactin protein analysis in tissue microarrays was used for correlation with clinical parameters, as well as for survival analysis. Gene expression profiling in HNSCC cells was performed to unreveal CTTN signaling.Results: Knockdown of CTTN in HNSCC cells showed less invasion in vitro. Gene expression profiling showed various deregulated genes known to be involved in progression. We confirmed the link between CTTN overexpression and progression in a large clinical cohort. High expression was associated with worse overall and progression‐free survival.Conclusions: We propose CTTN for managing OSCC in terms of adjuvant therapy and aftercare. Furthermore, our study reveals new potential targets in CTTN signaling for individualized OSCC therapy.
- 20 November 2018
- Published by Wiley in Head & Neck
- Vol. 40 (12) , 2685-2694
Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma
Background: Cortactin (CTTN) is located on chromosome 11q13 and is associated with invasiveness in various cancer entities. CTTN protein expression could be a prognosticator of oral squamous cell carcinoma (OSCC) in terms of recurrence and survival.Methods: CTTN‐dependent invasion was performed using migration assay in human papillomavirus‐negative head and neck squamous cell carcinoma (HNSCC) cells. Cortactin protein analysis in tissue microarrays was used for correlation with clinical parameters, as well as for survival analysis. Gene expression profiling in HNSCC cells was performed to unreveal CTTN signaling.Results: Knockdown of CTTN in HNSCC cells showed less invasion in vitro. Gene expression profiling showed various deregulated genes known to be involved in progression. We confirmed the link between CTTN overexpression and progression in a large clinical cohort. High expression was associated with worse overall and progression‐free survival.Conclusions: We propose CTTN for managing OSCC in terms of adjuvant therapy and aftercare. Furthermore, our study reveals new potential targets in CTTN signaling for individualized OSCC therapy.
- 25 September 2017
- Published by Wiley in Head & Neck
- Vol. 39 (12) , 2397-2405
Upregulation of pAKT(Ser473) expression in progression of HPV‐positive oropharyngeal squamous cell carcinoma
Background: PIK3CA alterations have been shown to be a frequent event in oropharyngeal squamous cell cancer (SCC), especially in human papillomavirus (HPV)‐related tumors.Methods: Tissue microarrays (TMAs) were used to evaluate pAKT(Ser473)/(Thr308), total protein kinase B (AKT)(pan) and phosphatase and tensin homolog (PTEN) expression in primary tumors and corresponding nodal disease in oropharyngeal SCC. The HPV status was determined in regard of HPV16 DNA and RNA. Survival analysis was performed by using Kaplan‐Meier curves, log‐rank testing, and multivariate Cox regression analysis.Results: HPV16 is a prognostic predictive marker for advanced oropharyngeal SCC. pAKT(Ser473) and PTEN are highly expressed in HPV‐related oropharyngeal SCCs in contrast to pAKT(Thr308). The pAKT(Ser473) expression increased from primary tumors to progressive nodal disease (21.1%; P < .011).Conclusion: Activation of phosphoinositide 3‐kinase (PI3K)/pAKT(Ser473) frequently occurs in advanced HPV‐positive oropharyngeal SCC and elevated pAKT(Ser473) levels represent a feature during progression of oropharyngeal SCC, indicating a critical role of the mammalian target of rapamycin (mTOR) complex. Further studies are required to evaluate specific drugs targeting PI3K/AKT/mTOR in consideration of PIK3CA alterations.
- 25 September 2017
- Published by Wiley in Head & Neck
- Vol. 39 (12) , 2397-2405
Upregulation of pAKT(Ser473) expression in progression of HPV‐positive oropharyngeal squamous cell carcinoma
Background: PIK3CA alterations have been shown to be a frequent event in oropharyngeal squamous cell cancer (SCC), especially in human papillomavirus (HPV)‐related tumors.Methods: Tissue microarrays (TMAs) were used to evaluate pAKT(Ser473)/(Thr308), total protein kinase B (AKT)(pan) and phosphatase and tensin homolog (PTEN) expression in primary tumors and corresponding nodal disease in oropharyngeal SCC. The HPV status was determined in regard of HPV16 DNA and RNA. Survival analysis was performed by using Kaplan‐Meier curves, log‐rank testing, and multivariate Cox regression analysis.Results: HPV16 is a prognostic predictive marker for advanced oropharyngeal SCC. pAKT(Ser473) and PTEN are highly expressed in HPV‐related oropharyngeal SCCs in contrast to pAKT(Thr308). The pAKT(Ser473) expression increased from primary tumors to progressive nodal disease (21.1%; P < .011).Conclusion: Activation of phosphoinositide 3‐kinase (PI3K)/pAKT(Ser473) frequently occurs in advanced HPV‐positive oropharyngeal SCC and elevated pAKT(Ser473) levels represent a feature during progression of oropharyngeal SCC, indicating a critical role of the mammalian target of rapamycin (mTOR) complex. Further studies are required to evaluate specific drugs targeting PI3K/AKT/mTOR in consideration of PIK3CA alterations.
- 1 July 2017
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 28 (5) , 1308-1310
Free Vastus Intermedius Muscle Flap
The reconstruction of large cranial and scalp defects is a surgical and esthetic challenge. Single autologous tissue transfer can be insufficient due to the defect size and the anatomic complexity of the recipient site. Alloplastic patient-specific preformed implants can be used to recover hard tissue defects of the neurocranium. Nevertheless, for long-term success adequate soft tissue support is required. In this brief clinical study, the authors describe calvarian reconstruction in a 33-year-old patient with wound healing disorder after an initial resection of ependymoma. The patient suffered from osteonecrosis and wound breakdown in the fronto-parietal region. An alloplastic polymethylmethacrylate implant for hard tissue support was manufactured based on 3-dimensional visualization of a computed tomography scan. After the resection of remaining pathologic bone from earlier surgical procedures, the alloplastic implant was inserted to achieve functional coverage of the brain. Due to anatomic variation of donor site vessels during anterolateral thigh flap preparation, the authors performed a vastus intermedius free flap as a new muscular flap for craniofacial reconstruction. The authors achieved excellent functional and esthetic results. The muscular vastus intermedius free flap in combination with a split skin graft proves to be a new alternative to the anterolateral thigh flap for soft tissue reconstruction of the neurocranium.
- 1 July 2017
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 28 (5) , 1308-1310
Free Vastus Intermedius Muscle Flap
The reconstruction of large cranial and scalp defects is a surgical and esthetic challenge. Single autologous tissue transfer can be insufficient due to the defect size and the anatomic complexity of the recipient site. Alloplastic patient-specific preformed implants can be used to recover hard tissue defects of the neurocranium. Nevertheless, for long-term success adequate soft tissue support is required. In this brief clinical study, the authors describe calvarian reconstruction in a 33-year-old patient with wound healing disorder after an initial resection of ependymoma. The patient suffered from osteonecrosis and wound breakdown in the fronto-parietal region. An alloplastic polymethylmethacrylate implant for hard tissue support was manufactured based on 3-dimensional visualization of a computed tomography scan. After the resection of remaining pathologic bone from earlier surgical procedures, the alloplastic implant was inserted to achieve functional coverage of the brain. Due to anatomic variation of donor site vessels during anterolateral thigh flap preparation, the authors performed a vastus intermedius free flap as a new muscular flap for craniofacial reconstruction. The authors achieved excellent functional and esthetic results. The muscular vastus intermedius free flap in combination with a split skin graft proves to be a new alternative to the anterolateral thigh flap for soft tissue reconstruction of the neurocranium.
- 1 August 2016
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 44 (8) , 1061-1066
Outcome of heavily pretreated recurrent oral squamous cell carcinoma after salvage resection: A monocentric retrospective analysis
- 1 August 2016
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 44 (8) , 1061-1066
Outcome of heavily pretreated recurrent oral squamous cell carcinoma after salvage resection: A monocentric retrospective analysis
- 1 May 2016
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 44 (5) , 626-631
Intracranial volume (ICV) in isolated sagittal craniosynostosis measured by 3D photocephalometry: A new perspective on a controversial issue
- 1 May 2016
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 44 (5) , 626-631
Intracranial volume (ICV) in isolated sagittal craniosynostosis measured by 3D photocephalometry: A new perspective on a controversial issue